162 related articles for article (PubMed ID: 38323765)
41. Calcium metabolism & hypercalcemia in adults.
Lumachi F; Motta R; Cecchin D; Ave S; Camozzi V; Basso SM; Luisetto G
Curr Med Chem; 2011; 18(23):3529-36. PubMed ID: 21756230
[TBL] [Abstract][Full Text] [Related]
42. Electrolytes: Calcium Disorders.
Barstow C; Braun M
FP Essent; 2017 Aug; 459():29-34. PubMed ID: 28806048
[TBL] [Abstract][Full Text] [Related]
43. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
Reagan P; Pani A; Rosner MH
Am J Kidney Dis; 2014 Jan; 63(1):141-7. PubMed ID: 24021907
[TBL] [Abstract][Full Text] [Related]
44. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
45. [Hypercalcemia as an emergency].
Rosenmund A
Schweiz Med Wochenschr; 1993 Apr; 123(15):735-8. PubMed ID: 8488377
[TBL] [Abstract][Full Text] [Related]
46. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
47. Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D; Drake MT; Crowley RK
Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
[TBL] [Abstract][Full Text] [Related]
48. A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia.
Tonon CR; Silva TAAL; Pereira FWL; Queiroz DAR; Junior ELF; Martins D; Azevedo PS; Okoshi MP; Zornoff LAM; de Paiva SAR; Minicucci MF; Polegato BF
Med Sci Monit; 2022 Feb; 28():e935821. PubMed ID: 35217631
[TBL] [Abstract][Full Text] [Related]
49. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
[TBL] [Abstract][Full Text] [Related]
50. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
51. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
52. Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism.
Parfitt AM; Schipani E; Rao DS; Kupin W; Han ZH; Jüppner H
J Clin Endocrinol Metab; 1996 Oct; 81(10):3584-8. PubMed ID: 8855805
[TBL] [Abstract][Full Text] [Related]
53. Overview of hypercalcemia of malignancy.
Solimando DA
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S4-7. PubMed ID: 11757205
[TBL] [Abstract][Full Text] [Related]
54. Medical treatment of malignancy-associated hypercalcemia.
Lumachi F; Brunello A; Roma A; Basso U
Curr Med Chem; 2008; 15(4):415-21. PubMed ID: 18288996
[TBL] [Abstract][Full Text] [Related]
55. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
Dawson C; Todd AM; Walton A
J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
[No Abstract] [Full Text] [Related]
56. Treatment of extreme hypercalcaemia: the role of haemodialysis.
Basok AB; Rogachev B; Haviv YS; Vorobiov M
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866671
[TBL] [Abstract][Full Text] [Related]
57. Primary hyperparathyroidism.
Silva BC; Cusano NE; Bilezikian JP
Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):593-607. PubMed ID: 30449543
[TBL] [Abstract][Full Text] [Related]
58. Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia.
Audran M; Minebois-Villégas A; Lortholary A; Legrand E; Pascaretti C; Giraud P; Subra JF; Boasson M; Jallet P
Rev Rhum Engl Ed; 1995 Mar; 62(3):189-96. PubMed ID: 7788336
[TBL] [Abstract][Full Text] [Related]
59. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy.
Sheehan MT; Wermers RA; Jatoi A; Loprinzi CL; Onitilo AA
Med Hypotheses; 2020 Oct; 143():110149. PubMed ID: 32763659
[TBL] [Abstract][Full Text] [Related]
60. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
